INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified data

Sayad Pierre Sargis reported FENC

Chief Medical Officer · FENNEC PHARMACEUTICALS INC. · Common shares

Side
M
Value
—
Shares
171
Price
—
Executed
Mar 31, 2026
Disclosed
Apr 2, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 31 executedApr 2, 2026 disclosed

FENC · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 0.9% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FENC

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    HS
    Hackman Jeffrey S.Director, Chief Executive Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    1,159 sh
    		Oct 31, 2026Nov 2, 2026
    traded Oct 31, 2026
    		+2dSEC FORM 4

    Evidence

    5
    SS
    Sayad Pierre SargisChief Medical Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Oct 31, 2026Nov 2, 2026
    traded Oct 31, 2026
    		+2dSEC FORM 4

    Evidence

    9
    EL
    Evans Terry LChief Commercial Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Oct 31, 2026Nov 2, 2026
    traded Oct 31, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CM
    Cioffi Christiana MarieChief Strategy Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    156 sh
    		Oct 31, 2026Nov 2, 2026
    traded Oct 31, 2026
    		+2dSEC FORM 4

    Evidence

    13
    CM
    Cioffi Christiana MarieChief Strategy Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A$22K
    3,946 sh
    		Oct 12, 2026Oct 13, 2026
    traded Oct 12, 2026
    		+1dSEC FORM 4

    Evidence

    13
    SS
    Sayad Pierre SargisChief Medical Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A$21K
    3,846 sh
    		Oct 12, 2026Oct 13, 2026
    traded Oct 12, 2026
    		+1dSEC FORM 4

    Evidence

    13
    EL
    Evans Terry LChief Commercial Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A$13K
    2,326 sh
    		Oct 12, 2026Oct 13, 2026
    traded Oct 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hackman Jeffrey S.Director, Chief Executive Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A$12K
    2,224 sh
    		Oct 12, 2026Oct 13, 2026
    traded Oct 12, 2026
    		+1dSEC FORM 4

    Evidence

    5
    SS
    Sayad Pierre SargisChief Medical Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cioffi Christiana MarieChief Strategy Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    156 sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    EL
    Evans Terry LChief Commercial Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hackman Jeffrey S.Director, Chief Executive Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    1,159 sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Sayad Pierre SargisChief Medical Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Aug 31, 2026Aug 31, 2026
    traded Aug 31, 2026
    		+0dSEC FORM 4

    Evidence

    36
    SS
    Sayad Pierre SargisChief Medical Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Open-market sale
    		SELL$146K
    12.0K sh
    		Aug 31, 2026Aug 31, 2026
    traded Aug 31, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CM
    Cioffi Christiana MarieChief Strategy Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    156 sh
    		Aug 31, 2026Aug 31, 2026
    traded Aug 31, 2026
    		+0dSEC FORM 4

    Evidence

    9
    HS
    Hackman Jeffrey S.Director, Chief Executive Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    1,159 sh
    		Aug 31, 2026Aug 31, 2026
    traded Aug 31, 2026
    		+0dSEC FORM 4

    Evidence

    9
    EL
    Evans Terry LChief Commercial Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Aug 31, 2026Aug 31, 2026
    traded Aug 31, 2026
    		+0dSEC FORM 4

    Evidence

    9
    EL
    Evans Terry LChief Commercial Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Jun 30, 2026Jul 1, 2026
    traded Jun 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hackman Jeffrey S.Director, Chief Executive Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    1,159 sh
    		Jun 30, 2026Jul 1, 2026
    traded Jun 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Sayad Pierre SargisChief Medical Officer
    FENCFENNEC PHARMACEUTICALS INC.
    Grant or award
    		A—
    168 sh
    		Jun 30, 2026Jul 1, 2026
    traded Jun 30, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002043395-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 31, 2026
    Published
    Apr 2, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    Sayad Pierre Sargis
    Role
    Chief Medical Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    FENNEC PHARMACEUTICALS INC.
    Ticker
    FENC
    Shares
    171
    Price per share
    $0
    Execution date (reported)
    Mar 31, 2026
    Owned after transaction
    18.6K shares
    Days from execution to publication
    2

    What this establishes

    Sayad Pierre Sargis filed this Form 4 reporting a option exercise of FENC on Mar 31, 2026. It became public on Apr 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Sayad Pierre Sargiscik:0002043395
    Issuer
    FENNEC PHARMACEUTICALS INC.cik:0001211583

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.